Skip to content
Back to TARA

Protara Therapeutics, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 17, 2025
Transactions
3
Purchases
0
Sales
3
Purchase value
$0.00
Sale value
$1.01M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Jesse SheffermanDirector · CEO and President
4
Filed Jul 1, 2026Period of report Jun 29, 20260001213900-26-074238
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 29, 2026
Common StockF1215,687$4.09$882.16K721,832Direct
Filing footnotes · 4
  1. F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.03 to $4.14, inclusive. The reporting person undertakes to provide to TARA, any security holder of TARA, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  2. F2The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest, and this report should not be deemed an admission that the Reporting Person or any other person named herein is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
  3. F3The reported securities held by the Samhold Family Trust were inadvertently included under the Reporting Person's direct holdings in the prior Form 4 filings filed by the Reporting Person on January 21, 2026, January 22, 2026 and January 27, 2026.
  4. F425% of the shares underlying the option vested on January 19, 2025 and the remaining shares have vested or will vest in equal monthly installments thereafter over the following 36 months, subject to the Reporting Person's continuous service with the Issuer as of each such date.
Open on SEC EDGAR
Jacqueline ZummoChief R&D Officer
4
Filed Apr 9, 2026Period of report Apr 8, 20260001213900-26-042079
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 8, 2026
Common StockF11,134$5.40$6.12K94,827Direct
Filing footnotes · 1
  1. F1The sale reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan established by the reporting person on December 31, 2025.
Open on SEC EDGAR
Jacqueline ZummoChief R&D Officer
4
Filed Apr 2, 2026Period of report Apr 1, 20260001213900-26-039328
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 1, 2026
Common StockF1F222,598$5.26$118.87K95,961Direct
Filing footnotes · 2
  1. F1The sale reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan established by the reporting person on December 31, 2025.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.25 to $5.31, inclusive. The reporting person undertakes to provide to TARA, any security holder of TARA, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.